Ameriprise
GLUE icon

Ameriprise’s Monte Rosa Therapeutics GLUE Stock Holding History

Ameriprise’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592K Sell
35,997
-86,167
-71% -$1.65M ﹤0.01% 3525
2025
Q4 		$1.92M Buy
+122,164
New +$1.65M ﹤0.01% 3026
2023
Q2 		– Sell
-10,955
Closed -$85.3K – 3940
2023
Q1 		$85.3K Sell
10,955
-1,754
-14% -$12.2K ﹤0.01% 3843
2022
Q4 		$97K Sell
12,709
-377
-3% -$3.14K ﹤0.01% 3811
2022
Q3 		$107K Buy
+13,086
New +$120K ﹤0.01% 3814

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ameriprise's GLUE Position: Q1 2026 in Review

Ameriprise reduced its Monte Rosa Therapeutics (GLUE) stake by 71% in Q1 2026, selling an estimated $1.65M and leaving 35,997 shares worth $592K. The position accounts for ﹤0.01% of the portfolio, ranked #3525.

Ameriprise first reported a position in GLUE in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.92M in Q4 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Ameriprise held 35,997 shares of Monte Rosa Therapeutics worth $592K as of Q1 2026.
  • Ameriprise sold 86,167 Monte Rosa Therapeutics shares in Q1 2026, an estimated $1.65M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3525 holding.
  • Ameriprise first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • Ameriprise's Monte Rosa Therapeutics position peaked at $1.92M in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.